On Friday, OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2.

The company is currently organizing additional data about the recently completed treatment phase of its Phase 2b trial of OST-HER2 to prevent recurrence of lung metastatic osteosarcoma in preparation for a Type B or Type C FDA.

Following the FDA meeting, the company anticipates submitting a Biologics Licensing Authorization (BLA) application to the FDA for accelerated or conditional approval consideration.

In January, OS Therapies revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.

The data demonstrate statistically significant results in the primary endpoint of the study, 12-month event-free survival (EFS), where an event is defined as the recurrence of metastatic osteosarcoma in OST-HER2-treated patients when compared with the published historical comparable control group.

Further, as of the most recent follow-up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival (‘OS,' remaining alive) at the 1-year and 2-year interim time points of the ongoing 3-year overall survival secondary endpoint.

In January, OS Therapies announced an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property (IP) assets from Ayala Pharmaceuticals.

OS Therapies will pay $0.5 million in cash and issue $7.5 million worth of common shares to Ayala.

OS Therapies previously disclosed that it completed a $7.1 million financing, priced at $4.00 per share, that provides the company with sufficient cash runway into 2026, including payments to Ayala.

Price Action: OSTX stock is up 28.6% at $2.58 at last check Friday.

Read Next:

• Matthews International Cashes In: Another $50M Sale Advances Debt Reduction Plan

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.